Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-sequencing of serial biopsies from 3 patients treated with Capivasertib (AZD5363)

ABSTRACT: RNA-sequencing of serial biopsies from 3 patients treated with Capivasertib (AZD5363)

PROVIDER: PRJNA609909 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11217950_1.fastq.gz	Fastqsanger.gz
	SRR11217950_2.fastq.gz	Fastqsanger.gz
	SRR11217951_1.fastq.gz	Fastqsanger.gz
	SRR11217951_2.fastq.gz	Fastqsanger.gz
	SRR11217952_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Stable gene expression of serial skin biopsies defines patient subsets in diffuse cutaneous systemic sclerosis

Project description:Systemic sclerosis (SSc) shows complex clinical manifestations including progressive skin and internal organ fibrosis. SSc can be divided into 'intrinsic subsets' by gene expression suggesting patient-specific heterogeneity in pathogenesis or temporal evolution of disease. Here we validate these subsets using an independent patient population, and test whether the genes vary over time with patients changing subsets as disease progresses, or if the genes are a stable feature of the patients within each subset. Skin biopsies were analyzed from 13 dSSc patients enrolled in an open label study of rituximab, 9 dSSc patients not treated with rituximab, and 9 healthy controls. These data recapitulate the patient 'intrinsic subsets' described previously with gene expression associated with cell proliferation, inflammatory processes, and a normal-like group. Serial skin biopsies showed consistent and non-progressing gene expression. We were unable to detect significant differences in gene expression before and after rituximab treatment, consistent with an apparent lack of clinical response. Serial biopsies from each patient stayed within the same gene expression subset regardless of treatment regimen or the time point at which they were taken. This demonstrates the intrinsic subsets are an inherent, reproducible and stable feature of SSc that is independent of disease duration.

2012-03-23 | GSE32413 | GEO

Stable gene expression of serial skin biopsies defines patient subsets in diffuse cutaneous systemic sclerosis

2012-03-23 | E-GEOD-32413 | biostudies-arrayexpress

Gene expression profiles of pretreatment biopsies from dose-dense-docetaxel-treated breast cancers

2011-04-22 | GSE28796 | GEO

Gene expression data from serial samples of follicular lymphoma (FLSB - follicular lymphoma serial biopsies)

Project description:Transformation of follicular lymphoma (FL) to a more aggressive disease is associated with rapid progression and death. Existing molecular markers for transformation are few and their clinical impact is limited. Here, we report on a whole-genome study of DNA copy numbers and gene expression profiles in serial FL biopsies. We identified 698 genes with high correlation between gene expression and copy number and the molecular network most enriched for these cis-associated genes. This network includes 14 cis-associated genes directly related to the NFκB pathway. For each of these 14 genes, the correlated NFκB target genes were identified and corresponding expression scores defined. The scores for six of the cis-associated NFκB pathway genes (BTK, IGBP1, IRAK1, ROCK1, TMED7-TICAM2 and TRIM37) were significantly associated with transformation. The results suggest that genes regulating B-cell survival and activation are involved in transformation of FL Expression profiles were obtained from 81 biopsies origniating from 41 patients diagnosed with follicular lymphoma using Affymetrix HG U133 Plus 2.0 Gene Chip. Of these, 49 biopsies were from 24 patients with subsequent transformation to higher-grade lymphoma (DLBCL) (43 with histological diagnosis FL and 6 with DLBCL) and 32 biopsies were from 17 patients without any signs transformation

2014-01-07 | E-GEOD-53820 | biostudies-arrayexpress

RNA-sequencing of serial biopsies from 3 patients treated with Capivasertib (AZD5363)

Project description:First line treatment with AKT inhibitors combined with paclitaxel improves outcomes of metastatic TNBC, especially in tumors that harbor mutations in PTEN/PIK3CA/AKT1. In this work, we refine the composite response biomarker to AZD5363 in this setting, which is relevant to inform the clinical development of these drugs.

2020-06-30 | GSE144794 | GEO

Gene expression profiles of pretreatment biopsies from dose-dense-docetaxel-treated breast cancers

Project description:The purpose of this study was to identify molecular markers of pathologic response to neoadjuvant dose-dense docetaxel treatment using gene expression profiling on pretreatment biopsies. Patients with high-risk, operable breast cancer were treated with 75 mg/m2 IV of docetaxel on day 1 of each cycle every 2 weeks x 4 cycles . Tumor tissue from pretreatment biopsies was obtained from 12 patients enrolled in the study. Gene expression profiling were done on serial sections of the biopsies from patients that achieved a pathologic complete response (pCR) and compared to those with residual disease, non-pCR (NR). Tumor tissues from pretreatment needle biopsies from patients enrolled in a dose-dense docetaxel clinical trial were laser capture microdissected for RNA extraction and hybridization to Affymetrix microarrays. We analyzed one array (sample A) from duplicate samples from each patient.

2011-04-22 | E-GEOD-28796 | biostudies-arrayexpress

RNAseq of scalp biopsies from EGFRi treated patients, who exhibited a folliculitis

Project description:RNAseq of scalp biopsies from EGFRi treated patients, who exhibited a folliculitis

| PRJEB67582 | ENA

RNA sequencing of endoscopic biopsies from patients with esophageal adenocarcinoma

Project description:RNA sequencing of endoscopic biopsies from patients with esophageal adenocarcinoma

| PRJNA855974 | ENA

Gene expression of baseline biopsies from etrolizumab-treated ulcerative colitis (UC) patients

Project description:RNA sequencing was performed on RNA isolated from baseline biopsies from UC patients enrolled in the Phase II EUCALYPTUS study of etrolizumab. Gene expression differences were identified in a subset of anti-TNF naÃ¯ve patients that achieved clinical remission at 10 weeks in response to etrolizumab. Baseline colonic biopsies from UC patients treated with etrolizumab were sequenced by the Illumina HiSeq 2000 Sequencing System.

2015-10-26 | E-GEOD-72819 | biostudies-arrayexpress

Gene expression data from serial samples of follicular lymphoma (FLSB - follicular lymphoma serial biopsies)

2014-01-07 | GSE53820 | GEO